Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1124918

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England’s service specification.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251321
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251322 251323 251324 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124919

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit’s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251322
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251321 251323 251324 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124920

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251323
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251321 251322 251324 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124921

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of the adequacy of the availability of Haemtrack in Haemophilia centres.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251324
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251321 251322 251323 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124923

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231466 on Hospitals: Infectious Diseases, whether work of Public Health England will also include as assessment of the effect of changes to ophthalmic surgical practice on trends in the level of risk of infection rates in hospitals.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251326
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Public Health England does not currently include ophthalmic surgery as part of mandatory or voluntary surveillance of surgical site infections.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:24:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124924

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231467 on Ophthalmic Services, whether he has made an assessment of the ability for clinicians to take into account patients’ wishes for concomitant treatment in relation to potential restrictions of the 2019/2020 NHS Tariff.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251327
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>For the 2017/19 national tariff (which was set for two years), the prices for BZ91 were manually increased above the initially modelled level (based on 2014/15 reference costs) following feedback from the ophthalmology Expert Working Group (EWG). For 2019/20, the EWG recommended that the prices for BZ91 should not be increased and should remain as modelled (based on 2016/17 reference costs).</p><p>The EWG also confirmed that minimally invasive glaucoma surgery (MIGS) and cataract activity are commonly done together and it would not usually be in the patient’s best interest to do them separately. The EWG advised that BZ91 was appropriate for combined MIGS and cataract activity – a MIGS procedure plus a cataract procedure should not receive over twice as much as either procedure alone.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:43:32 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124938

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Education: Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department is making on producing a public information campaign to educate the general public on the health impacts of air pollution, particularly in instances of moderate or high pollution episodes.
tabling member constituency	Penistone and Stocksbridge
tabling member printed	Angela Smith
uin	251250
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Public Health England and the Department for Environment, Food and Rural Affairs (Defra) are exploring whether social marketing can assist in awareness-raising about air pollution.</p><p>The Joint Air Quality Unit (JAQU) is planning a national-level campaign to support Clean Air Zones (CAZ) from summer 2019. This will raise awareness of the risks presented by high concentrations of nitrogen dioxide (NO2) and the implementation of charging CAZ. It will also promote long-term behaviour change by encouraging the public to change travel habits and reduce NO2 emissions.</p><p>The JAQU has also provided a CAZ communications toolkit to support local authorities in their local communications work. It contains key messages, frequently asked questions, useful statistics, infographics and other content to ensure a consistent approach is taken to raising awareness and to encourage drivers to consider alternative options in terms of travel and vehicle choice.</p><p>Defra is developing a communication strategy on domestic combustion for launch before the next winter burning season.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:30:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1564 label Biography information for Angela Smith

1124952

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Units (Use of Force) Act 2018
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timeframe is for bringing into force the provisions of the Mental Health Units (Use of Force) Act 2018.
tabling member constituency	Bermondsey and Old Southwark
tabling member printed	Neil Coyle
uin	251343
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>We remain committed to implementing fully the provisions within the Mental Health Units (Use of Force) Act 2018. We will work closely with key stakeholders in preparing the relevant statutory guidance and bring the legislation into force in due course.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/05/2019 16:10:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4368 label Biography information for Neil Coyle

1124972

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has plans to extend free prescriptions to people with phenylketonuria; and if he will make a statement.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	251355
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>The Department has no current plans to extend free prescriptions or to assess the merits of adding phenylketonuria (PKU) to the list of medical conditions that provide exemption from prescription charges. Extensive arrangements are already in place to help people afford National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions, for which someone with PKU may qualify.</p><p>To support those with greatest need who do not qualify for an exemption, prescription prepayment certificates are available. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251356 question first answered 15/05/2019 16:09:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4603 label Biography information for Preet Kaur Gill

1124973

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions: Fees and Charges
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of adding phenylketonuria to the list of medical exemptions for prescription charges.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	251356
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>The Department has no current plans to extend free prescriptions or to assess the merits of adding phenylketonuria (PKU) to the list of medical conditions that provide exemption from prescription charges. Extensive arrangements are already in place to help people afford National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions, for which someone with PKU may qualify.</p><p>To support those with greatest need who do not qualify for an exemption, prescription prepayment certificates are available. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251355 question first answered 15/05/2019 16:09:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4603 label Biography information for Preet Kaur Gill